Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Genmab A/S ADR
(NQ:
GMAB
)
28.38
+0.25 (+0.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Genmab A/S ADR
< Previous
1
2
3
4
5
6
Next >
Where Genmab Stands With Analysts
June 26, 2023
Via
Benzinga
Expert Ratings for Genmab
June 06, 2023
Via
Benzinga
FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients
May 19, 2023
The FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)...
Via
Benzinga
Recap: Genmab Q1 Earnings
May 10, 2023
Via
Benzinga
How To Attend Genmab Q1 2023 Earnings Conference Call
May 08, 2023
Via
Benzinga
Price Over Earnings Overview: Genmab
April 27, 2023
Via
Benzinga
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways: Analyst
April 24, 2023
Via
Benzinga
Analyst Ratings for Genmab
April 20, 2023
Via
Benzinga
P/E Ratio Insights for Genmab
April 11, 2023
Via
Benzinga
This Foreboding Sign Looms Over Genmab's Chart
March 31, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Genmab
March 01, 2023
Via
Benzinga
Earnings Outlook For Genmab
February 21, 2023
Via
Benzinga
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
April 17, 2023
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before.
Via
Investor's Business Daily
Alkermes Stock Sees Rising Relative Price Strength
February 17, 2023
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86.
Via
Investor's Business Daily
Moderna Stock Getting Closer To Key Technical Benchmark
February 10, 2023
On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier.
Via
Investor's Business Daily
Anavex Life Sciences Stock Shows Improved Price Strength Rating
February 07, 2023
Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75.
Via
Investor's Business Daily
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
January 19, 2023
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before.
Via
Investor's Business Daily
Vertex Pharmaceuticals Stock Sees Rising Relative Strength
January 11, 2023
A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
3 Biotech Companies to Watch in 2023
January 06, 2023
These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year.
Via
InvestorPlace
Moderna Stock Shows Surprising Strength; Key Rating Upgraded
December 14, 2022
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average.
Via
Investor's Business Daily
Our 7 Top Biotech Stock Picks for 2023
December 09, 2022
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.
Via
InvestorPlace
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
December 08, 2022
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier.
Via
Investor's Business Daily
3 Hot Stocks That Could Live Up to Their Lofty Valuations
December 08, 2022
These companies have long runways of growth ahead
Via
The Motley Fool
Is AbbVie Stock a Buy Now?
December 06, 2022
The pharmaceutical company prepared well as Humira approaches its patent cliff next year.
Via
The Motley Fool
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
November 29, 2022
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.
Via
Investor's Business Daily
Stocks That Hit 52-Week Lows On Friday
November 25, 2022
On Friday, 68 companies reached new 52-week highs.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
November 21, 2022
During Monday's session, 50 stocks hit new 52-week highs.
Via
Benzinga
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
November 11, 2022
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84.
Via
Investor's Business Daily
3 Hail Mary Plays to Bring Your Stock Portfolio Back From the Brink
October 25, 2022
You may have to take a shot on some riskier plays if you want to make up your portfolio's significant loss of yardage.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.